PhaseBio Pharmaceuticals Inc (PHAS)
Stock chart
Loading...
•
Purchase
•
Sale
•
Planned purchase
•
Planned sale
Net purchase
Net sale
Earnings
Earnings
Value bought
Past 90 days
Value sold
Past 90 days
Net insiders buying
Past 90 days
Trades (buy and sell)
Past 90 days
Search
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PS: Planned sale, O: Option / Other
| Notification date | Transaction date | B/S Transaction type | Insider and/or position |
Nb. shares Price Value |
Number of shares | Price | Value | Details |
|---|---|---|---|---|---|---|---|---|
| 2022-10-26 | 2022-10-25 | S Sale |
NEW ENTERPRISE ASSOCIATES 13 LP Large shareholder |
1,784,109
-26.9%
0.15USD 262,264 |
1,784,109 -26.9% | 0.15 | USD 262,264 | |
| 2022-05-24 | 2022-05-23 | PS Planned sale |
SVP of Human Resources Officer |
11,248
-100.0%
0.79USD 8,886 |
11,248 -100.0% | 0.79 | USD 8,886 | |
| 2021-11-23 | 2021-11-19 | PS Planned sale |
VP, Human Resources Officer |
5,766
-100.0%
2.37USD 13,665 |
5,766 -100.0% | 2.37 | USD 13,665 | |
| 2021-05-24 | 2021-05-20 | S Sale |
VP, Human Resources Officer |
3,811
-100.0%
3.29USD 12,538 |
3,811 -100.0% | 3.29 | USD 12,538 | |
| 2020-12-04 | 2020-12-03 | B Purchase | Non-Executive Director |
6,000
+inf%
4.12USD 24,720 |
6,000 +inf% | 4.12 | USD 24,720 | |
| 2020-11-24 | 2020-11-24 | B Purchase | Non-Executive Director |
2,000
+9.5%
3.50USD 7,000 |
2,000 +9.5% | 3.50 | USD 7,000 | |
| 2020-11-24 | 2020-11-23 | B Purchase | Non-Executive Director |
3,000
+16.7%
3.67USD 11,010 |
3,000 +16.7% | 3.67 | USD 11,010 | |
| 2020-11-23 | 2020-11-23 | S Sale |
VP, Human Resources Officer |
3,497
-100.0%
3.45USD 12,065 |
3,497 -100.0% | 3.45 | USD 12,065 | |
| 2019-07-03 | 2019-07-01 | PS Planned sale | Large shareholder |
459
-0.1%
14.00USD 6,426 |
459 -0.1% | 14.00 | USD 6,426 | |
| 2019-07-03 | 2019-07-01 | PS Planned sale | Large shareholder |
255
-0.5%
14.00USD 3,570 |
255 -0.5% | 14.00 | USD 3,570 | |
| 2019-07-03 | 2019-07-01 | PS Planned sale | Large shareholder |
180
-0.1%
14.00USD 2,520 |
180 -0.1% | 14.00 | USD 2,520 | |
| 2019-07-03 | 2019-07-01 | PS Planned sale | Large shareholder |
2,014
-0.1%
14.00USD 28,196 |
2,014 -0.1% | 14.00 | USD 28,196 | |
| 2019-06-20 | 2019-06-18 | PS Planned sale | Large shareholder |
63
-0.0%
14.00USD 882 |
63 -0.0% | 14.00 | USD 882 | |
| 2019-06-20 | 2019-06-18 | PS Planned sale | Large shareholder |
35
-0.1%
14.00USD 490 |
35 -0.1% | 14.00 | USD 490 | |
| 2019-06-20 | 2019-06-18 | PS Planned sale | Large shareholder |
25
-0.0%
14.00USD 350 |
25 -0.0% | 14.00 | USD 350 | |
| 2019-06-20 | 2019-06-18 | PS Planned sale | Large shareholder |
277
-0.0%
14.00USD 3,878 |
277 -0.0% | 14.00 | USD 3,878 | |
| 2018-12-17 | 2018-12-17 | B Purchase | Non-Executive Director |
1,000
+inf%
4.46USD 4,460 |
1,000 +inf% | 4.46 | USD 4,460 | |
| 2018-12-17 | 2018-12-13 | B Purchase |
Ballance David James VP, Research and Sci. Affairs Officer |
1,000
+15.2%
3.94USD 3,940 |
1,000 +15.2% | 3.94 | USD 3,940 | |
| 2018-12-17 | 2018-12-13 | B Purchase |
Chief Executive Officer Executive Director |
1,000
+2.0%
3.69USD 3,690 |
1,000 +2.0% | 3.69 | USD 3,690 | |
| 2018-12-11 | 2018-12-11 | B Purchase |
York Michael VP, Corporate Development Officer |
1,500
+inf%
3.88USD 5,820 |
1,500 +inf% | 3.88 | USD 5,820 |